Roivant Sciences Ltd. ( ROIV ) is a late-stage autoimmune and rare-disease company that currently has three subsidiaries called Vants: 1) Priovant, 2) Immunovant, and 3) Pulmovant. Priovant is working on Brepocitinib in Phase 3 for dermatomyositis (DM) and has an NDA targeted for 1H2026. Immunovant is developing IMVT-1402 as aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in comp ...